|
WO2021072244A1
|
|
Anti-tn antibodies and uses thereof
|
|
WO2021067865A1
|
|
Diagnosis and treatment of thyroid cancer
|
|
WO2021067628A2
|
|
Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells
|
|
WO2021067170A1
|
|
Rapid antimicrobial susceptibility testing by image analysis
|
|
WO2021062217A1
|
|
Anti-inflammatory therapy in arrhythmogenic cardiomyopathy (acm)
|
|
WO2021022224A1
|
|
Compounds, pharmaceutical compositions, and methods of their use in the inhibition of interaction between il18 and il18r
|
|
WO2021016521A1
|
|
Photo induced control of protein destruction
|
|
WO2020257700A2
|
|
Lymphatic anastomosis devices
|
|
WO2020243416A2
|
|
Methods for generation of tumor organoid-fished t cells and identification of anti-tumor t cell receptors
|
|
WO2020236645A1
|
|
Compositions and methods for homology directed repair
|
|
WO2020227524A1
|
|
Systems and methods for quantitative ecg heterogeneity-guided optimization of therapeutic efficacy of implantable cardiac devices
|
|
US2020281621A1
|
|
Image guided spinal decompression with contralateral oblique view
|
|
WO2020180876A1
|
|
Orai channel inhibitors
|
|
WO2020172274A1
|
|
Targeting micrornas to overcome drug tolerance and resistance
|
|
WO2020163591A1
|
|
Compositions and methods for characterizing pancreatic ductal adenocarcinoma
|
|
WO2020146770A1
|
|
Methods for the prevention or treatment of cytokine storm, and for preventing diseases or conditions caused by cytokine storm
|
|
WO2020132133A1
|
|
Generation of organoid-primed t (opt) cells with memory phenotype
|
|
WO2020123806A1
|
|
Modulation of pd-1
|
|
WO2020117867A1
|
|
Darinaparsin and retinoic acid compounds for treatment of idh-associated disorders
|
|
WO2020117868A1
|
|
Arsenic compounds and retinoic acid compounds for treatment of idh-associated disorders
|
